Table 3. Participant Characteristics by Clinical Trial.
| Characteristic | Naltrexone (n=607) | Varenicline (n=198) | Topiramate (n=364) | |||
|---|---|---|---|---|---|---|
| Medication (n=302) | Placebo (n=305) | Medication (n=97) | Placebo (n=101) | Medication (n=179) | Placebo (n=185) | |
| Age, mean (SD), y | 44.2 (10.4) | 43.9 (10.1) | 46.0 (11.0) | 45.0 (12.3) | 46.7 (9.4) | 47.8 (8.7) |
| Men, No. (%) | 211 (69.9) | 207 (67.9) | 71 (73.2) | 69 (68.3) | 133 (74.3) | 133 (71.9) |
| Race/ethnicity, No. (%) | ||||||
| White | 227 (75.2) | 241 (79.0) | 60 (619) | 71 (70.3) | 152 (84.9) | 157 (84.9) |
| Black | 30 (9.9) | 21 (6.9) | 30 (30.9) | 27 (26.7) | 13 (7.3) | 17 (9.2) |
| Hispanic | 39 (12.9) | 34 (11.1) | 2 (2.1) | 2 (2.0) | 12 (6.7) | 7 (3.8) |
| Other | 6 (2.0) | 9 (3.0) | 5 (5.2) | 1 (1.0) | 2 (1.1) | 4 (2.2) |
| Educational level (<high school), No. (%) | 94 (31.1) | 89 (29.2) | 37 (38.1) | 29 (28.7) | NA | NA |
| Alcohol consumption (baseline) | ||||||
| Abstinent, No. (%) | 0 | 0 | 0 | 0 | 0 | 0 |
| No heavy drinking days, No. (%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Percent days abstinent, mean (SD) | 22.6 (21.8) | 21.3 (22.0) | 7.7 (12.5) | 7.9 (13.6) | 10.9 (16.0) | 9.7 (15.0) |
| Percent heavy drinking days, mean (SD) | 67.3 (27.2) | 68.5 (26.9) | 88.1 (15.8) | 87.2 (16.4) | 82.4 (19.6) | 83.8 (19.4) |
| Drinks per day, mean (SD) | 8.6 (6.2) | 8.4 (5.6) | 14.2 (9.3) | 12.5 (8.9) | 10.0 (4.4) | 9.6 (3.9) |
| Drinks per drinking day, mean (SD) | 11.2 (6.8) | 10.9 (6.7) | 15.3 (9.6) | 13.6 (9.0) | 11.4 (4.8) | 10.9 (4.3) |
| WHO risk level, No. (%) | ||||||
| Low | 14 (4.6) | 3 (1.0) | 0 | 0 | 0 | 0 |
| Medium | 25 (8.3) | 25 (8.2) | 0 | 1 (1.0) | 2 (1.1) | 2 (1.1) |
| High | 58 (19.2) | 67 (22.0) | 23 (23.7) | 28 (27.7) | 58 (32.4) | 60 (32.4) |
| Very high | 205 (67.9) | 210 (68.9) | 74 (76.3) | 72 (71.3) | 119 (66.5) | 123 (66.5) |
Abbreviations: NA, not available; WHO, World Health Organization.